Clinical Trial Update: Study of Erlotinib and Metformin in Triple Negative Breast Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the combination of Erlotinib and Metformin in triple-negative breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Tarceva (erlotinib)
• metformin (metformin)

Snippet

Sponsor: Columbia University | Conditions: Breast Cancer | Phase 1 | Status: COMPLETED